GKN2 and gastric cancer: Thus, in the present study, the loss of expression of gastrokine-2 protein in human gastric cancer tissue samples was confirmed, and then a functional-grade purified anti-human CD95 (APO/Fas) antibody was used to activate, and an anti-Fas (human, neutralizing, clone ZB4) antibody was used to block the extrinsic pathway following transfection of gastrokine-2.